<DOC>
	<DOCNO>NCT00325442</DOCNO>
	<brief_summary>This study international , multi-center , randomize , double-blind , placebo-controlled study subject PAH currently receive approve therapy PAH ( i.e. , endothelin receptor antagonist and/or phosphodiesterase-5 inhibitor ) . Study visit occur 4 week interval 16 week ; key measure efficacy 6-minute walk test . Study procedure include routine blood test , medical history , physical exam , disease evaluation , exercise test . One optional substudy also part FREEDOM-C select center - hemodynamic substudy right heart catheterization Baseline Week 16 . Patients complete assessment 16-weeks also eligible enter open-label , extension phase study ( FREEDOM - EXT ) .</brief_summary>
	<brief_title>FREEDOM-C : Oral Treprostinil Combination With Endothelin Receptor Antagonist ( ERA ) and/or Phosphodiesterase-5 ( PDE-5 ) Inhibitor Treatment Pulmonary Arterial Hypertension ( PAH )</brief_title>
	<detailed_description />
	<mesh_term>Hypertension</mesh_term>
	<mesh_term>Hypertension , Pulmonary</mesh_term>
	<mesh_term>Familial Primary Pulmonary Hypertension</mesh_term>
	<mesh_term>Endothelin Receptor Antagonists</mesh_term>
	<mesh_term>Phosphodiesterase 5 Inhibitors</mesh_term>
	<mesh_term>Treprostinil</mesh_term>
	<criteria>Between 12 70 year age , inclusive . Body weight least 45 kg ( approximately 100 pound ) . PAH either idiopathic/heritable ( include PAH associate appetite suppressant/toxin use ) ; PAH associate repaired congenital systemictopulmonary shunt ( repair â‰¥ 5 year ) ; PAH associate collagen vascular disease ; PAH associate HIV . Baseline 6minute walk distance 150 450 meter , inclusive . Currently receive approve endothelin receptor antagonist and/or approve phosphodiesterase5 inhibitor least 90 day stable dose least last 30 day . Previous test ( e.g. , right heart catheterization , echocardiography ) consistent diagnosis PAH . Reliable cooperative protocol requirement . Nursing pregnant . Received prostacyclin within past 30 day . PAH due condition note inclusion criterion . History uncontrolled sleep apnea , renal insufficiency , anemia , leave sided heart disease , uncontrolled systemic hypertension , parenchymal lung disease . Use investigational drug within 30 day Baseline .</criteria>
	<gender>All</gender>
	<minimum_age>12 Years</minimum_age>
	<maximum_age>70 Years</maximum_age>
	<verification_date>February 2017</verification_date>
	<keyword>Pulmonary Arterial Hypertension</keyword>
</DOC>